Moleculin Biotech, Inc. (MBRX) announced it has been granted a patent from the Mexican Patent Office, strengthening the global intellectual property portfolio for its proprietary lung-targeted liposomal Annamycin technology. The filing also disclosed recent financing activities through its At-The-Market (ATM) offering.

Key Details

  • Patent Grant: The company was granted Mexican Patent No. 436849, which protects its Annamycin technology and remains in force until November 23, 2040.
  • Financing Activity: In September 2026, the company issued 888,400 shares of common stock through its ATM offering, raising aggregate gross proceeds of $0.48 million.
  • Warrant Repricing: Due to the ATM share issuance, the exercise price of the company's Series I Warrants was reduced from $0.75 per share to $0.51 per share as a result of anti-dilution provisions.